There is an urgent need for new treatments to improve clinical outcomes and survival for patients with glioblastoma.
Glioblastoma is the most common type of primary, malignant and very aggressive brain tumour with around 2,200 cases diagnosed each year in England.
Standard treatment usually involves surgery (if possible) to remove the tumour. This is often followed by radiotherapy and chemotherapy.
Dr Paul Mulholland is a consultant medical oncologist at The National Hospital for Neurology and Neurosurgery. He is very optimistic about new treatments including immunotherapy for treating glioblastoma. An immunotherapy drug, ipilimumab has been approved in Europe for use in patients with advanced melanoma and brain metastases (secondary tumours). More than 18% of patients who received this immunotherapy drug in a clinical trial were alive after five years compared to only 8% who did not.
The National Brain Appeal has committed to raise £250,000 to support the running costs of the trial.